Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures

被引:75
作者
Meyer, T
Nindl, I
Schmook, T
Ulrich, C
Sterry, W
Stockfleth, E
机构
[1] Inst Immunol Clin Pathol & Mol Med, D-22339 Hamburg, Germany
[2] Univ Hosp Charite, Dept Dermatol, D-10117 Berlin, Germany
关键词
apoptosis; imiquimod; mode of action; TLR;
D O I
10.1046/j.0366-077X.2003.05632.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Toll-like receptor (TLR)-7 agonists represent a new group of immune response modifiers, which include imiquimod and resiquimod (R-848). Topically applied imiquimod is used for the treatment of both external and perianal genital warts, and benign and malignant epithelial lesions. Based on the induction of interferons and other cytokines in vitro and in vivo, regression of epithelial lesions probably depends on induction of both innate and cellular immune responses. As clinical remission is not always associated with inflammation, other mechanisms may also be involved. Using two different assays for detection of apoptosis (TUNEL test and gel analysis of DNA fragmentation), we observed induction of apoptosis by imiquimod in human epithelial cell lines (HeLa S3) and keratinocytes (HaCaT, A431 cells), as well as in mouse fibroblasts (McCoy cells). These findings suggest that the mode of action of imiquimod to eliminate virus-infected, dysplastic or neoplastic epithelial cells may also include the induction of apoptotic processes.
引用
收藏
页码:9 / 13
页数:5
相关论文
共 19 条
[1]   Toll-like receptor-2 transduces signals for NF-κB activation, apoptosis and reactive oxygen species production [J].
Aliprantis, AO ;
Weiss, DS ;
Zychlinsky, A .
JOURNAL OF ENDOTOXIN RESEARCH, 2001, 7 (04) :287-291
[2]   TIRAP mediates endotoxin-induced NF-κB activation and apoptosis in endothelial cells [J].
Bannerman, DD ;
Erwert, RD ;
Winn, RK ;
Harlan, JM .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 295 (01) :157-162
[3]   Treatment of genital warts with an immune-response modifier (imiquimod) [J].
Beutner, KR ;
Spruance, SL ;
Hougham, AJ ;
Fox, TL ;
Owens, ML ;
Douglas, JM .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1998, 38 (02) :230-239
[4]   The immune response modifier resiquimod mimics CD40-induced B cell activation [J].
Bishop, GA ;
Ramirez, LM ;
Baccam, M ;
Busch, LK ;
Pederson, LK ;
Tomai, MA .
CELLULAR IMMUNOLOGY, 2001, 208 (01) :9-17
[5]   Self-administered topical 5% imiquimod cream for external anogenital warts [J].
Edwards, L ;
Ferenczy, A ;
Eron, L ;
Baker, D ;
Owens, ML ;
Fox, TL ;
Hougham, AJ ;
Schmitt, KA .
ARCHIVES OF DERMATOLOGY, 1998, 134 (01) :25-30
[6]   Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway [J].
Hemmi, H ;
Kaisho, T ;
Takeuchi, O ;
Sato, S ;
Sanjo, H ;
Hoshino, K ;
Horiuchi, T ;
Tomizawa, H ;
Takeda, K ;
Akira, S .
NATURE IMMUNOLOGY, 2002, 3 (02) :196-200
[7]   Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum [J].
Hengge, UR ;
Esser, S ;
Schultewolter, T ;
Behrendt, C ;
Meyer, T ;
Stockfleth, E ;
Goos, M .
BRITISH JOURNAL OF DERMATOLOGY, 2000, 143 (05) :1026-1031
[8]   Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848 [J].
Jurk, M ;
Heil, F ;
Vollmer, J ;
Schetter, C ;
Krieg, AM ;
Wagner, H ;
Lipford, G ;
Bauer, S .
NATURE IMMUNOLOGY, 2002, 3 (06) :499-499
[9]  
KONO T, 1994, LYMPHOKINE CYTOK RES, V13, P71
[10]   Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicenter 6-week dose-response trial [J].
Marks, R ;
Gebauer, K ;
Shumack, S ;
Amies, M ;
Bryden, J ;
Fox, TL ;
Owens, ML .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 44 (05) :807-813